Private Firms Step Up Microgravity Drug R&D and Develop Commercial Space Stations as ISS Deorbit Nears

PharmaVoice USA

Overview

As the International Space Station (ISS) approaches deorbit, private companies are taking the lead to continue microgravity drug research and development (R&D). Despite the proven success of over a decade of protein crystallization research on the ISS directly contributing to Merck & Co.’s Keytruda reformulation and FDA approval, the ISS National Lab faces budget cuts. Companies like Redwire and Vast (partnering with SpaceX) are conducting experiments, such as improving gold nanosphere production for nanomedicine, and advancing plans to deploy commercial space stations as ISS replacements.

In Depth

Key Findings

With the International Space Station (ISS) nearing its deorbit, concerns have arisen that critical microgravity-based drug research and development (R&D) might be lost. However, private companies are stepping up, leading the charge in developing commercial space stations and committing to continuing microgravity research. The invaluable impact of ISS protein crystallization and organoid research on terrestrial medical applications has already been firmly established.

Technical & Clinical Details

Years of research on the ISS have illuminated the unique effects of microgravity on biological processes, opening new avenues for drug discovery. One of the most notable successes is Merck & Co.’s achievement in reformulating the anticancer drug Keytruda into a more stable version, which received FDA approval, as a direct result of over a decade of protein crystallization research on the ISS. This demonstrates that microgravity enables the growth of high-quality crystals that are difficult to achieve on Earth. Companies like Redwire are conducting experiments to improve the production efficiency of gold nanospheres for nanomedicine, with the potential for more uniform and precise nanoparticles to be applied in drug delivery systems and diagnostic tools. Vast, in partnership with SpaceX, is advancing plans to deploy the Haven-1 commercial space station, which is expected to serve as a critical microgravity research platform replacing the ISS.

Background & Industry Context

The ISS is slated for deorbit in the early 2030s, raising concerns about a potential gap in microgravity research. The ISS National Lab faces the harsh reality of budget cuts to sustain its operations, meaning the future of space-based scientific research increasingly relies on the active participation of the private sector. Biotechnology and pharmaceutical companies recognize the unique advantages microgravity offers for cell culture, tissue engineering, disease modeling, and novel drug candidate screening. The development of commercial space stations by private entities will expand access to research space and enable cost-effective continuation of microgravity research. This is a noticeable trend in the life sciences sector, reflecting a broader paradigm shift in space development from government-led to privately-led initiatives.

Future Outlook

The success of commercial space stations led by private companies will solidify microgravity as a new frontier for drug discovery and biotechnology. Once Vast’s Haven-1 and other private platforms become operational, more research institutions and companies will be able to participate in space-based experiments, potentially accelerating the development of groundbreaking treatments for diseases that are difficult to cure on Earth, such as cancer, neurodegenerative diseases, and autoimmune disorders. Furthermore, advancements in in-orbit manufacturing technologies will enable materials science applications impossible on Earth, bringing new value not only to the pharmaceutical industry but also to various other sectors. The legacy of the ISS will not be lost but is expected to lead to even greater innovation in this new commercial space era.